Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0325814116
Thu, 10.10.2024
Kuros Biosciences AG
Financial Highlights
Direct MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine months of 2024, from CHF 20.4 million in the same period in 2023
Total Kuros Medical Devices segment sales accelerated to CHF 51.1 million in Q3 2024 from CHF 21.3 million in Q3 2023 year to date
Kuros Medical Devices segment EBITDA increased to CHF [ … ]
Thu, 08.08.2024
Kuros Biosciences AG
Financial Highlights
Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; this corresponds to a sequential increase of 62% or CHF 12.1 million over H2 2023
Total Kuros Medical Devices segment sales increased 148% to CHF 31.8 million from CHF 12.9 million
Kuros Medical Devices segment EBITDA increased 287 [ … ]
Wed, 24.04.2024
Kuros Biosciences AG
Financial Highlights
Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023; this corresponds to a sequential increase of 21.9% or CHF 2.5 million over Q4 2023
Total Kuros Medical Devices segment sales accelerated to CHF 13.9 million in Q1 2024 from CHF 5.6 million in Q1 2023
Kuros Medical Devices segm [ … ]
Wed, 13.03.2024
Kuros Biosciences AG
Financial highlights
Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million in 2022. Total medical device sales accelerated by 153% from CHF 13.3 million in 2022 to CHF 33.6 million in 2023
The Medical Devices segment achieved a positive EBITDA of CHF 6.8 million driven by MagnetOs
Cash and cash equivalen [ … ]
Wed, 27.12.2023
Kuros Biosciences AG
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population (20% smokers). In the STRUCTURE trial, MagnetOs mixed with autograft showed posterolateral fusion rates comparable to autograft fusion rates in the less challenging interbody space
I [ … ]
Thu, 12.10.2023
Kuros Biosciences AG
Direct MagnetOs sales grew to CHF 20.4 million in the first nine months of 2023, climbing from CHF 8.1 million in the same period in 2022. Total medical device sales accelerated from CHF 9.0 million to CHF 21.3 million
The Medical Devices segment achieved a positive EBITDA of CHF 3.8 million driven by MagnetOs
Cash & cash equivalents amounte [ … ]
Wed, 09.08.2023
Kuros Biosciences AG
Financial Highlights
Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue from medical devices rose from CHF 5.7 million to CHF 12.9 million
Medical Devices segment achieved a positive EBITDA of CHF 2.2 million driven by MagnetOs
Cash & cash equivalents amounted to CHF 16.9 million, funds available [ … ]
Mon, 08.05.2023
Kuros Biosciences AG
Schlieren (Zurich), Switzerland, May 8, 2023 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today.
The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2022 and took note of the Reports of t [ … ]
Mon, 08.05.2023
Kuros Biosciences AG
Schlieren (Zurich), Switzerland, May 8, 2023 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today.
The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2022 and took note of the Reports of t [ … ]
Thu, 27.04.2023
Kuros Biosciences AG
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Direct MagnetOs sales climbed from CHF 2.0 million in Q1 2022 to CHF 5.4 million in Q1 2023. Total medical device sales accelerate from 2.6 million to CHF 5.6 million
Key data on efficacy of MagnetOs bone graft published in two prestigious, peer-reviewed scientific journals
Kuros [ … ]